Abstract
The management of invasive aspergillosis continues to pose challenging issues. The review herein focuses on our evolving knowledge base with regards to the evolution of disease upon initiation of antifungal therapy, approach to worsening disease despite seemingly adequate therapy, and therapeutic considerations in the prescription of antifungal agents for invasive aspergillosis in patients receiving iatrogenic immunosuppressants. Evidence-based studies are still needed to resolve critical issues pertaining to combination therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
